11/15/2023 | News release | Distributed by Public on 11/15/2023 06:32
Antibiotice SA (ATB symbol) submitted to the Bucharest Stock Exchange, on Wednesday, November 15, 2023, the report containing the economic-financial results related to the first 9 months of 2023.
The data in the report reflect sustainable growth of the company's business, which is part of the trend provided by the multi-annual business plan "The Future Together", for the period 2023-2030, which pursues objectives such as capitalizing on production capacity, attracting new products and increasing the market share of products in the portfolio, doubling turnover and profitability.
The company's achievements in the first 9 months of 2023 aligned with the business plan "The Future Together 2023 - 2030":
Consolidated financial results
The financial balance indicators pursued in the first 9 months of 2023 are:
Total bank debt (amount of bank debt as an expression of the operating credit balance and the investment credit balance):
32% increase in turnover in the internal market
In the first 9 months of this year, Antibiotice achieved a turnover on the Romanian market in the amount of RON 288.67 million, increasing by 32% compared to the first 9 months of 2022. This increase was determined by optimizing marketing policies, attracting new products, repositioning medicines in the portfolio, as well as strengthening the therapeutic class for systemic use and dermatological preparations, cardiovascular system and digestive tract, where Antibiotice are positioned in the first places in the internal market. The company is a quantitative leader in the total pharmaceutical market for injections (56%), ointments (20.6%), suppositories and eggs (35.7%).
The sale of Antibiotice brand drugs on market segments in the first 9 months of 2023, compared to the same period of 2022, is as follows:
During the analyzed period, the food supplements in the Nutriensa® range, which registered significant developments in sales, are the brands SimbiFlora, Lejer® and Immunofix®.
Business in international markets growing by 23.3%
Between January and September 2023, the net turnover on international markets was RON 174.76 million, increasing by 23.3% compared to the same period of 2022. This result was obtained by exporting a number of 80 drugs, totaling a volume of approximately 68 million therapeutic units, increasing compared to previous years. Significant increases were recorded in territories such as: USA, Vietnam, UK, Moldova, Denmark, Hungary, the Netherlands, which generated 90% of the sales of the analyzed period. In these territories, Antibiotice is positioned in the top of producers offering complete portfolios of anti-infectious drugs administered in hospitals. Export recovery (over 55 countries) of biotechnologies derived from nourse streptomycins for pharmaceutical use (compacted nystatin, micronized nystatin and standard nystatin), determined in the first 9 months of this year a 14% increase in sales, compared to the first 9 months of the previous year.
The portfolio of evolving products, the premise of the company's long-term development
In the first 9 months of 2023, the company's portfolio was completed with 10 new products requested by the market:
Sustainable development through strategic investment projects
In order to sustainably develop, the company made in the first 9 months of 2023 total investments amounting to RON 51.03 million, compared to RON 32.3 million made in the first 9 months of the previous year. One of the major investments that Antibiotice targets for the sustainable development of the company is the one dedicated to the project "Capacity for the production, packaging and storage of sterile products, solutions and topical products", part of the business plan "The Future Together". The manufacture of these new types of medicines will contribute to supporting the national health system as well as to increasing the company's exports, with an impact on the increase in turnover in the 2030s.
For this project, whose total value is over RON 200 million, Antibiotice obtained non-reimbursable funds in the amount of RON 85 million through state aid from the Ministry of Finance and concluded a loan agreement, without request for guarantees, with the European Investment Bank, worth RON 123 million. During the analyzed period, the first works related to this investment were started by starting the construction of a modern warehouse of finished products that has a storage capacity three times higher than that of the warehouse existing on the platform, fully digitized. The new warehouse will be adapted to the estimated production in the perspective of the following years (2030).
Sustainable development to ensure the conservation of resources for future generations and a healthier environment is a key direction of the company's sustainability strategy. In this regard, Antibiotice invested in the production of green energy from renewable sources obtaining non-reimbursable financing through PNRR funds in order to build photovoltaic parks both on the ground (2.5 MW), as well as on buildings (1.2 MW), which will provide 36.4% of the company's own energy consumption, from energy produced 100% of renewable resources. Both projects will be completed this year.